Pharmacological prevention of colorectal cancer

Practical Gastroenterology

Volumn 31, Issue 10, 2007, Pages 20-36

  Half, Elizabeth ^a   Arber, Nadir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC; URSODEOXYCHOLIC ACID;

ADENOMATOUS POLYP; CANCER PREVENTION; CANCER RISK; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFECT; DRUG INDICATION; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; NEPHROTOXICITY; REVIEW; RISK ASSESSMENT; STOMACH INJURY; STROKE; THROMBOCYTE DYSFUNCTION; TREATMENT RESPONSE;

EID: 41149089792     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Jemal, A., et al. Cancer statistics, 2006. CA Cancer J Clin, 2006;56(1): 106-130.
2. NCI-C, National Cancer Institute of Canada, Canadian Cancer Statistics. www.cancer.ca, 2003.
3. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin, 1999; 49:33-64.
4. Walsh J, Terdiman J. Colorectal cancer screening. JAMA, 2003; 289:1288-1296.
5. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut, 1982;23(10): 835-842.
6. Winawer SJ, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. NEJM, 1993;329(27):1977-1981.
7. Lynch HT, Smyrk T, Lynch J. An update of HNPCC (Lynch syndrome). Cancer Genet Cytogenet, 1997; 93(1): 84-99.
8. Half EE, Bresalier RS. Clinical management of hereditary colorectal cancer syndromes. Curr Opin Gastroenterol, 2004;20(1): 32-42.
9. Herschman HR, Xie W, Reddy S. Inflammation, reproduction, cancer and all that.... The regulation and role of the inducible prostaglandin synthase. Bioessays, 1995;17(12):1031-1037.
10. Eberhart CE, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994. 107(4):1183-1188.
11. Sinicrope FA, et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology, 1999; 117(2):350-358.
12. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. NEJM, 2001;345(6): 433-442.
13. Oshima M, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 1996;87(5): 803-809.
14. Gupta RA, DuBois RN. Aspirin, NSAIDS, and colon cancer prevention: mechanisms? Gastroenterology, 1998;114(5): 1095-1098.
15. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, 2006; 98:736-747.
16. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol, 1996;52:237-245.
17. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res, 1999;59:4356-4362.
18. Thun MJ, Namboodiri MM, Heath CW, Jr. Aspirin use and reduced risk of fatal colon cancer. NEJM, 1991;325(23): 1593-1596.
19. Giovannucci E, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med, 1994;121(4): 241-246.
20. Giovannucci E, et al. Aspirin and the risk of colorectal cancer in women. NEJM, 1995; 333(10): 609-614.
21. Sturmer T, et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med, 1998;128(9): 713-720.
22. Smalley W, et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med, 1999;159(2): 161-166.
23. Chan AT, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med, 2004;140(3):157-166.
24. Allison M, Garland C, Chlebowski R, Criqui M, Langer R, Wu L, Roy H, McTiernan A, Kuller L, and for the Women's Health Initiative Investigators. The Association between Aspirin Use and the Incidence of Colorectal Cancer in Women. Am J Epidemiol, 2006;164(6):567-575. Epub 2006 Jul 17.
25. Waddell WR, et al. Sulindac for polyposis of the colon. Am J Surg, 1989,157(1): 175-179.
26. Giardiello FM, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. NEJM, 1993;328(18): 1313-1316.
27. Giardiello FM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. NEJM, 2002;346(14): 1054-1059.
28. Steinbach G, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. NEJM, 2000; 342(26): 1946-1952.
29. Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. NEJM, 2003;348(10): 883-890.
30. Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas. NEJM, 2003;348(10): 891-899.
31. Benamouzig R, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology, 2003;125(2):328-336.
32. Ladabaum U, et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med, 2001;135(9):769-781.
33. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology, 2002;122(1): 78-84.
34. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. NEJM, 2006, 355:873-884.
35. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. NEJM, 2006;355:885-895.
36. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology, 2006;131(6):1674-1682. Epub 2006 Sep 1.
37. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. NEJM, 2005;352(11):1092-1102.
38. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. NEJM, 2005;352:1071-1080.
39. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 2006;114: 1028-1035.
40. Wallace JL, Del Soldato P. The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol, 2003;17(1):11-20.
41. Mizoguchi H, Hase S, Tanaka A, Takeuchi K. Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats. Aliment Pharmacol Ther, 2001; 15(2):257-267.
42. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med, 2004;10(7):324-330.
43. Velazquez C, Praveen Rao PN, Knaus EE. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J Med Chem, 2005;48(12):4061-4067.
44. Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G, et al. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci, 1998;62(23):PL 367-373.
45. Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther, 2006;5(6):1530-1538.
46. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun, 2004;313(3):784-788.
47. Swamy MV, Cooma I, Reddy BS, Rao CV. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int J Oncol, 2002; 20(4):753-759.
48. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology, 1999;117(4):838-847.
49. Narisawa T, Fukaura Y, Terada K, Umezawa A, Tanida N, Yazawa K, et al. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis, 1994; 15(9):2045-2048.
50. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med, 1996;156(18):2085-2092.
51. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. NEJM, 1996; 335(14):1001-1009.
52. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. NEJM, 2005;352(21):2184-2192.
53. Hori T, Matsumoto K, Sakaitani Y, et al. Effect of dietary deoxycholic acid and cholesterol on fecal steroid concentration and its impact on the colonic crypt cell proliferation in azoxymethane-treated rats. Cancer Lett, 1998;124:79-84.
54. Cohen BI, Raicht RF, Deschner EE, et al. Effect of cholic acid feeding on N-methyl-N-nitrosourea-induced colon tumors and cell kinetics in rats. J Natl Cancer Inst, 1980;64: 573-578.
55. Luk GD, Baylin SB. Ornithine decarboxylase as a biologic marker in familial colonic polyposis. NEJM, 1984;311(2): 80-83.
56. Rozhin J, Wilson PS, Bull AW, Nigro ND. Ornithine decarboxylase activity in the rat and human colon. Cancer Res, 1984;44(8):3226-3230.
57. Hixson LJ, Garewal HS, McGee DL, Sloan D, Fennerty MB, Sampliner RE, et al. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev, 1993;2(4):369-374.
58. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am, 2002;31(4):925-943.
59. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin, 2000;50(1):7-33.
60. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW, Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst, 1995;87(7):517-523.
61. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002;288(3):321-333.
62. Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res, 2006;66(8):4542-4546.
63. Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res, 2000;60(7):1864-1870.
64. Jacoby RF, Cole CE, Hawk ET, Lubet RA. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology, 2004;127(3):838-844.